Research overview: FIV vaccine development and the dual-subtype approach

Developing an FIV vaccine proved difficult because lentiviruses mutate rapidly and protective immunity is hard to elicit. A commercial inactivated dual-subtype whole-virus vaccine was eventually marketed in some regions, but field efficacy against diverse circulating clades and the problem of vaccine-induced antibodies confounding standard antibody tests limited adoption, and the product was later withdrawn in several markets. This overview compiles the vaccine literature rather than one citation, describing why cross-clade protection is the central challenge, how vaccination complicated serologic diagnosis until PCR-based tests matured, and why FIV vaccine research continues to inform HIV vaccine science. It matters because the feline experience illustrates both the promise and the persistent obstacles of lentiviral immunization.